Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15153MR)

This product GTTS-WQ15153MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases, Pemphigus vulgaris (PV) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15153MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1262MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ10741MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ14491MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ8088MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ7219MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ7988MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GX-H9
GTTS-WQ12417MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ9134MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN-289
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW